for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innoviva Inc

INVA.OQ

Latest Trade

14.61USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.21

 - 

14.68

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.61
Open
--
Volume
--
3M AVG Volume
13.77
Today's High
--
Today's Low
--
52 Week High
14.68
52 Week Low
9.21
Shares Out (MIL)
69.40
Market Cap (MIL)
985.43
Forward P/E
8.54
Dividend (Yield %)
--

Next Event

Q3 2021 Innoviva Inc Earnings Release

Latest Developments

More

Innoviva Reports Second Quarter 2021 Financial Results

GSK Announces Sale Of Stake In Innoviva Inc

Innoviva Reports Q1 EPS $0.84

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Innoviva Inc

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Industry

Biotechnology & Drugs

Contact Info

1350 OLD BAYSHORE HIGHWAY, SUITE 400

BURLINGAME, CA

94010

United States

+1.650.2389600

https://www.inva.com/

Executive Leadership

Odysseas D. Kostas

Independent Chairman of the Board

Pavel Raifeld

Chief Executive Officer

Marianne Y. Zhen

Chief Accounting Officer

George W. Bickerstaff

Independent Director

Deborah L. Birx

Independent Director

Key Stats

4.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.3K

2019

0.3K

2020

0.3K

2021(E)

0.2K
EPS (USD)

2018

1.750

2019

1.430

2020

2.020

2021(E)

1.660
Price To Earnings (TTM)
5.75
Price To Sales (TTM)
2.70
Price To Book (MRQ)
2.98
Price To Cash Flow (TTM)
4.16
Total Debt To Equity (MRQ)
118.26
LT Debt To Equity (MRQ)
118.26
Return on Investment (TTM)
43.28
Return on Equity (TTM)
40.41

Latest News

Latest News

Britain's GSK exits U.S. drugmaker Innoviva in $392 million deal

GlaxoSmithKline has sold its entire stake in Innoviva back to the U.S.-based company for about $392 million, the British drugmaker said on Thursday, as it simplifies operations ahead of a split into two businesses.

BRIEF-GSK Announces Sale Of Stake In Innoviva Inc

* GSK - SHARES TO BE SOLD BACK TO INNOVIVA AT $12.25 PER SHARE

BRIEF-Theravance Biopharma Says Received From Innoviva Draft TRC Quarterly Financial Plan

* THERAVANCE BIOPHARMA - ON JUNE 1, 2020 RECEIVED FROM INNOVIVA DRAFT TRC QTRLY FINANCIAL PLAN FOR QUARTER ENDING SEPT 30, 2020

BRIEF-Innoviva Names Pavel Raifeld As Chief Executive Officer

* INNOVIVA INC - APPOINTMENT OF PAVEL RAIFELD AS CEO EFFECTIVE MAY 20, 2020

BRIEF-Innoviva Reports First Quarter 2020 Financial Results

* QTRLY EARNINGS PER SHARE $0.59 Source text for Eikon: Further company coverage:

BRIEF-Innoviva, Inc Reports 19.996% Stake In Entasis Therapeutics Holdings As Of April 22

* INNOVIVA, INC REPORTS 19.996% STAKE IN ENTASIS THERAPEUTICS HOLDINGS AS OF APRIL 22 - SEC FILING Source text: [https://bit.ly/2zoeuFf] (Reuters.Briefs@thomsonreuters.com)

BRIEF-Entasis Therapeutics Entered Into Securities Purchase Agreement With Innoviva

* ENTASIS THERAPEUTICS- ON APR 12, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT WITH INNOVIVA

BRIEF-Innoviva Says Co's 2020 Annual Meeting Of Stockholders Will Be Held In Virtual Meeting Format Only

* INNOVIVA INC - CO'S 2020 ANNUAL MEETING OF STOCKHOLDERS WILL BE HELD IN VIRTUAL MEETING FORMAT ONLY Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up